Abstract:Rationale: Pulmonary vascular endotheliitis, perivascular inflammation, and immune activation are observed in COVID-19 patients. While the initial SARS-CoV-2 infection mainly infects lung epithelial cells, whether it also infects endothelial cells (ECs) and to what extent SARS-CoV-2-mediated pulmonary vascular endotheliitis is associated with immune activation remain to be determined. Methods: To address these questions, we studied SARS-CoV-2-infected K18-hACE2 (K18) mice, a severe COVID-19 mouse model, as well as lung samples from SARS-CoV-2-infected nonhuman primates (NHP) and patient deceased from COVID-19. We used immunostaining, RNAscope, and electron microscopy to analyze the organs collected from animals and patient. We conducted bulk and single cell (sc) RNA-seq analyses, and cytokine profiling of lungs or serum of the severe COVID-19 mice. Results: We show that SARS-CoV-2-infected K18 mice develop severe COVID-19, including progressive body weight loss and fatality at 7 days, severe lung interstitial inflammation, edema, hemorrhage, perivascular inflammation, systemic lymphocytopenia, and eosinopenia. Body weight loss in K18 mice correlated with the severity of pneumonia, but not with brain infection. We also observed endothelial activation and dysfunction in pulmonary vessels evidenced by the up-regulation of VCAM1 and ICAM1 and the downregulation of VE-cadherin. We detected SARS-CoV-2 in capillary ECs, activation and adhesion of platelets and immune cells to the vascular wall of the alveolar septa, and increased complement deposition in the lungs, in both COVID-19-murine and NHP models. We also revealed that pathways of coagulation, complement, K-ras signaling, and genes of ICAM1 and VCAM1 related to EC dysfunction and injury were upregulated, and were associated with massive immune activation in the lung and circulation. Conclusion: Together, our results indicate that SARS-CoV-2 causes endotheliitis via both infection and infection-mediated immune activation, which may contribute to the pathogenesis of severe COVID-19 disease.

Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Small molecules inhibit SARS-COV-2 induced aberrant inflammation and viral replication in mice by targeting S100A8/A9-TLR4 axis

Single-Cell Landscape of Lungs Reveals Key Role of Neutrophil-Mediated Immunopathology during Lethal SARS-CoV-2 Infection

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

FPR1 signaling aberrantly regulates S100A8/A9 production by CD14 + FCN1 hi macrophages and aggravates pulmonary pathology in severe COVID-19

Pathogenic neutrophilia drives acute respiratory distress syndrome in severe COVID-19 patients

Immune Characteristic Genes and Neutrophil Immune Transformation Studies in Severe COVID-19

Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus

Interferon‐responsive neutrophils and macrophages extricate SARS‐CoV‐2 Omicron critical patients from the nasty fate of sepsis

Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19

HIF-dependent induction of alveolar miR-147 dampens SARS-CoV-2 immune evasion

Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice

Paracrinal regulation of neutrophil functions by coronaviral infection in iPSC-derived alveolar type II epithelial cells

Comparative single-cell analysis reveals IFN-γ as a driver of respiratory sequelae after acute COVID-19

Transcriptional reprogramming of infiltrating neutrophils drives lung pathology in severe COVID-19 despite low viral load

IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19

Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome

Endothelial cell infection and dysfunction, immune activation in severe COVID-19

Aberrant pathogenic GM-CSF<sup>+</sup> T cells and inflammatory CD14<sup>+</sup>CD16<sup>+</sup> monocytes in severe pulmonary syndrome patients of a new coronavirus